Patient preferences for prenatal testing and termination of pregnancy for congenital anomalies and genetic diseases in Ethiopia by Brooks, Daniel et al.
Received: 25 January 2019 Revised: 25 April 2019 Accepted: 1 May 2019
DOI: 10.1002/pd.5472OR I G I N A L A R T I C L EPatient preferences for prenatal testing and termination of
pregnancy for congenital anomalies and genetic diseases in
EthiopiaDaniel Brooks1 | Katharine Asta1 | Julie Sturza2 | Birhanu Kebede3 | Delayehu Bekele3 |
Balkachew Nigatu3 | Jenny Hewison4 | Shane C. Quinonez51University of Michigan Medical School, Ann
Arbor, MI, USA
2Department of Pediatrics, University of
Michigan Medical School, Ann Arbor, MI, USA
3Department of Obstetrics and Gynecology,
St. Paul's Hospital Millennium Medical College,
Addis Ababa, Ethiopia
4Centre for Health Services Research, Leeds
Institute of Health Sciences, University of
Leeds, Leeds, UK
5Department of Pediatrics, Division of
Genetics, Metabolism, and Genomic Medicine,
University of Michigan, Ann Arbor, MI, USA
Correspondence
Shane C. Quinonez, Department of Pediatrics,
Division of Genetics, Metabolism, and
Genomic Medicine, University of Michigan,
D5240 Medical Professional Building, 1500 E.
Medical Center Drive, Ann Arbor, MI 48109,
USA.
Email: squinon@med.umich.edu
Funding information
Student Biomedical Research Program (SBRP)
through the University of Michigan Medical
SchoolPrenatal Diagnosis. 2019;39:595–602.Abstract
Objective: As prenatal diagnostic services expand throughout low‐income
countries, an important consideration is the appropriateness of these services for
patients. In these countries, services now include prenatal ultrasound and occasion-
ally genetic testing. To assess patient interest, we surveyed pregnant patients at a
hospital in Addis Ababa, Ethiopia, on their preferences for prenatal testing and
termination of affected pregnancies for congenital anomalies and genetic diseases.
Method: One hundred one pregnant patients were surveyed on their preferences
for prenatal testing and termination of affected pregnancies using a survey covering
various congenital anomalies and genetic diseases.
Results: Eighty‐nine percent of patients reported interest in testing for all condi-
tions. Three percent of patients were not interested in any testing. Over 60% of
patients reported interest in termination for anencephaly, early infant death, severe
intellectual disability, hemoglobinopathy, and amelia. Patients were more likely to
express interest in prenatal testing and termination for conditions associated with a
shortened lifespan.
Conclusion: Ethiopian patients were interested in prenatal testing and termination
of pregnancy for many conditions. Advancing prenatal diagnostic capacities is a
potential strategy for addressing the incidence of congenital anomalies and genetic
disease in Ethiopia. Importantly, there exist many factors and technological limitations
to consider before implementation.1 | INTRODUCTION
Over the last two decades, noncommunicable diseases (NCDs) have
increased as a cause of worldwide disability and mortality.1,2 Con-
comitant with this increase has been a decrease in disability and mor-
tality from communicable, maternal, neonatal, and nutritional
conditions.1 This change in disease prevalence mirrors the epidemio-
logical shift countries experience when they improve communicable
disease control and the delivery of care to pregnant women, infants,wileyonlinelibrary.comand children resulting in an increase in the relative burden of congen-
ital anomalies and genetic disease.3 Low‐ and middle‐income coun-
tries (LMICs) are especially susceptible to this transition as they
comprise 94% of all congenital anomalies with genetic or partially
genetic origin.4,5 As LMICs advance their abilities to treat communica-
ble diseases and to provide peripartum and perinatal care to women
and children, respectively, the burden of congenital anomalies and
genetic disease steadily increases in incidence and public health
importance.3© 2019 John Wiley & Sons, Ltd./journal/pd 595
What's already known about this topic?
• Prenatal genetic services are expanding throughout many
low‐ and middle‐income countries.
• In low‐ and middle‐income countries, little is known on
patient preferences for prenatal testing for congenital
anomalies and genetic diseases and patient interest in
termination of affected pregnancies.
What does this study add?
• Patients at St. Paul's Hospital in Addis Ababa, Ethiopia,
were interested in prenatal testing and termination of
pregnancy for many congenital anomalies and genetic
diseases.
• Studying patient preferences for genetic services in a
low‐income country is possible and should be
considered prior to the introduction of a new service
and/or technology.
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Health Organization has outlined a set of recommendations to address
congenital anomalies and genetic disease referred to as Community
Genetics.6 Community Genetics aims to provide services to individuals
while working to reduce the incidence of congenital anomalies and
genetic diseases at the population level.6,7 Examples of successful
programs include those targeting sickle cell disease in Cameroon,
Jamaica, Tanzania, and Nigeria and those addressing thalassemias
in Bahrain, Iran, and Cyprus.8-14 Importantly, each country has a
unique set of disorders and cultural and religious beliefs requiring
consideration prior to program implementation.3
Previous work has evaluated the public's preferences for prenatal
testing (PNT) and termination of pregnancies (TOP) for various con-
genital anomalies and genetic diseases.8,15-20 These studies have
investigated a range of issues, particularly related to economic, social,
and cultural considerations, such as how certain religious values
impact preferences for TOP and the influence of gender on attitudes
towards PNT based on cultural norms related to child‐rearing.8,15-20
The majority of these studies have been limited to high‐ and middle‐
income countries with the only work performed in a lower middle‐
income country (Ghana) limited to preferences for sickle cell disease
prenatal testing.18 Other work has focused on PNT and TOP for select
conditions such as hearing loss, familial adenomatous polyposis, and
oral clefts.21-24 Importantly, no previous work has investigated the
broad preferences of pregnant women in a low‐income country.
The use of PNT and the termination of those affected with a
congenital anomaly and/or genetic disease have been used in many
community genetics programs.5,6,25 In many low‐income countries,
the ability to diagnose these conditions is increasing as the result of
improving ultrasound diagnosis and prenatal genetic diagnosis.26,27
While these advances have the potential to impact a country's
incidence of congenital anomalies and genetic disease, there exist
multiple ethical, cultural, and legal considerations that must be made
prior to the broad introduction of prenatal diagnostic services.3
Primary among these considerations are the preferences of pregnant
women for PNT and TOP.
In Ethiopia, TOP is important to consider given the recent legal
expansion of safe abortion services.28 There is limited epidemiological
data on genetic conditions or congenital anomalies in Ethiopia with no
national standard screening used in pregnancy.29,30 However, St.
Paul's Hospital Millennium Medical College (SPHMMC) in Addis
Ababa, Ethiopia, a low‐income country, has recently improved their
ability to prenatally screen for and diagnose congenital anomalies
and genetic diseases. This has been accomplished through the training
of maternal‐fetal medicine (MFM) specialists with prenatal ultrasound
expertise, genetic counseling education of nurses, and in‐country
diagnostic genetic testing able to detect pregnancies affected with
aneuploidies and select microdeletion/microduplication syndromes.
Furthermore, use of a mobile application, the MiGene Family History
App, has been used as a tool to introduce medical genetics services
while simultaneously collecting epidemiologic congenital anomaly
and genetic disease data.30 While the treatment of congenital
anomalies and genetic diseases is limited in Ethiopia and at SPHMMC,there is ongoing capacity building in multiple areas important for the
management of these conditions. Examples at SPHMMC include
fellowship‐trained pediatric specialists important for the care of
patients with congenital anomalies and genetic diseases including
those in cardiology, neonatology, nephrology, and endocrinology.
SPHMMC surgical expertise has also expanded and includes a
well‐established kidney transplant program.
The introduction of clinical services in Ethiopia has resulted in
increased patient access to PNT and the potential for TOP if desired.
Increased access to medical care has been shown to drastically
improve birth outcomes and women's autonomy in Ethiopia, which is
important given their historical lack of decision making and author-
ity.31,32 As the introduction of PNT and TOP services requires a
significant amount of planning, time, and cost, we aimed to investigate
patient preferences for these services at SPHMMC. The information
learned from this work may prove useful for various stakeholders
including health care providers, public health specialists, and the
Ethiopian Ministry of Health as they consider expanding prenatal
services into other hospitals and regions. To assess patient prefer-
ences for these services, we surveyed pregnant women in the
SPHMMC antenatal clinic on their preferences for prenatal testing
and TOP for multiple congenital anomalies and genetic diseases.2 | METHODS
2.1 | Survey design
The patient survey was adapted from that previously designed by
Hewison et al.16 The survey contained questions with descriptions
of 14 congenital anomalies and genetic disorders instead of using
medical terminology to avoid preconceived ideas of conditions and
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ogy. The conditions were chosen to reflect a wide range of disorders
encompassing physical, mental, and sensory deficits to provide a broad
assessment of participants' attitudes.16 As an example, a question
would be asked as follows: “A child would be born without a brain
and die before or soon after birth. Would you want a prenatal test?”
“Prenatal test” was used as rapid advancements in genetic testing
in Ethiopia that have increased the available testing options,
although the current standard of care at SPHMMC is amniocentesis
and aneuploidy testing. In a separate question, participants were asked
if they would consider TOP if the test showed the fetus had the
condition. Answer choices for condition questions were yes, no, and
not sure.
As the survey was completed on pregnant women, it also
inquired about gestational age, the number of previous pregnancies,
participant age, and if a previous pregnancy had resulted in a child
born with a congenital anomaly or genetic condition. The survey was
available in English and Amharic, the national language of Ethiopia,
and was translated independently by two Ethiopian physicians with
a consensus version used as the final version.TABLE 1 Participant characteristics
Mean (range)
Patient age 28 (19‐37)
Gestational age 31.9 (7‐42)
Number of pregnancies 2.4 (1‐5)
Previous times pregnant Number (%)2.2 | Patient recruitment
The study was approved by IRBs at both The University of Michigan
and SPHMMC. Consent forms were available in English and Amharic.
Participants were recruited from pregnant women awaiting their
appointment in the antenatal clinic at SPHMMC. The majority of
women approached for participation agreed to participate. Three
women chose not to participate but did not provide a reason.
SPHMMC is the second largest Ethiopian public hospital and provides
most of its care to an underserved population often from surrounding
rural areas. Participants were read questions by two SPHMMC
Ob/Gyn residents with answers recorded on printed surveys.
There was no situation where a man was present when a woman
was asked to participate nor during survey administration. Surveys
took approximately 5 to 10 minutes per participant. The physicians
that facilitated the survey were trained on survey administration
including limiting extraneous information outside of the language
printed on the survey. If asked a clarifying question, they were
trained to repeat the description of the condition as printed on the
translated survey.1 time 21 (21%)
2 times 40 (40%)
3 times 27 (27%)
4 times 8 (8%)
5 or more times 5 (5%)
Previous pregnancy with a birth defect/genetic
disease
Yes 4 (4%)
No 76 (75%)
Not sure 1 (1%)2.3 | Statistical analysis
We used median age (28 years) as a cut point to split responders into
two groups for comparison. Fisher exact test was used to compare
responses between the two maternal age groups (less than 28 y vs
greater than/equal to 28 y) to examine if there was an age‐related
difference. Similarly, we used median gestational age (34.5 wk) to
split responders into two groups for comparison as this may influence
decisions for PNT and TOP. Fisher exact test was also used tocompare responses between the two gestational age groups (less
than 34.5 wk vs greater than/equal to 34.5 wk).
Among women who had a previous birth, we compared the
responses of the women who had a previous pregnancy that resulted
in a child born with a congenital anomaly, congenital anomalies, or a
suspected genetic condition (n = 4) to those who had not or were
unsure (n = 77) using Fisher exact test. We also assessed group
differences based on the number of pregnancies and used three
groups for comparison: pregnant once, pregnant twice, and pregnant
three or more times using Fisher exact test to compare responses
between the three groups.
To determine if individuals were more likely to choose PNT or TOP
if conditions were associated with a shortened lifespan, a repeated
measures logistic regression was run, modeling responses to PNT or
TOP question (yes or no, omitted “not sure” for purposes of this
model) as predicted by whether or not conditions included a short-
ened lifespan. Repeated measures analysis was used to deal with the
fact that an individual's responses to all questions would be expected
to be correlated, allowing us to remove variability due to individual
differences between subjects.3 | RESULTS
3.1 | Participant characteristics
A total of 101 participants were enrolled in the study. Table 1
shows the characteristics of participants. The average age of
participants was 28 years old (n = 101; SD, 4.6; range, 19‐37 y)
with the average gestational age of 31.9 weeks (n = 88; SD, 8.2; range,
7‐42 wk) and an average of 2.4 total pregnancies per participant
(n = 101; SD, 1.1; range, 1‐5 previous pregnancies). Of the participants
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vious pregnancy affected with a congenital anomaly or suspected
genetic condition, and 95% (n = 76) had no history of a child
affected with a congenital anomaly or genetic condition.3.2 | Participants' preferences for prenatal testing
Figure 1 shows the summary of patient responses regarding prefer-
ences for PNT for the 14 conditions surveyed. Of the 101 surveyed
patients, 89% reported wanting testing for all conditions while only
3% did not want testing for any of the inquired conditions. The only
conditions for which respondents were unsure of wanting testing
were those describing children with severe intellectual disability,
short stature, and behavioral and intellectual disabilities.
In our cohort, the median age of respondents was 28 years.
When comparing responses between those less than 28 years and
those greater than or equal to 28 years, there was no statistically
significant difference in the desire for PNT for any of the inquired
conditions. Similarly, the median gestational age was 34.5 weeks
with no statistically significant differences noted for PTN for any
of the conditions between groups less than 34.5 weeks gestationFIGURE 1 Patient preferences for prenatal genetic testing for 14 condit
can be viewed at wileyonlinelibrary.com]and those greater than or equal to 34.5 weeks. There was also no
difference in preferences for PNT for any of the conditions when
comparing respondents who had a previous pregnancy affected with
a congenital anomaly (n = 4) to those who either were unsure or had
not had a previous pregnancy affected with a congenital anomaly
(n = 77). Additionally, no differences were seen for preferences
for PNT between groups based on their number of previous
pregnancies.3.3 | Participants' preferences for termination of
pregnancy
Figure 2 shows the summary of patient responses regarding TOP for
the 14 conditions surveyed. Seventeen percent of patients would
not consider termination for any of the described conditions. Greater
than 60% of respondents would consider TOP for the following
conditions: anencephaly, early infant death, severe intellectual
disability, hemoglobinopathy, and amelia. There was no statistically
significant difference between age groups regarding interest for
TOP for any of the inquired conditions. In terms of gestational age,
no difference was seen between those less than 34.5 weeks andions. ID, intellectual disability; MD, muscular dystrophy [Colour figure
FIGURE 2 Patient preferences for termination of pregnancy for 14 surveyed conditions. ID, intellectual disability; MD, muscular dystrophy
[Colour figure can be viewed at wileyonlinelibrary.com]
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besides blindness. In those with a gestational age greater than or
equal to 34.5 weeks, only 6.8% would consider termination for
blindness (P value = .02). When comparing those with a previous
pregnancy affected with a congenital anomaly (n = 4) to those
without a previous pregnancy affected with a congenital anomaly
(n = 77), no difference was seen in their preferences for TOP for
any of the conditions.
When comparing groups by number of previous times pregnant,
no differences were seen for interest in TOP for all but one of the
conditions. For those women with one pregnancy, 14.3% would
consider termination for blindness; for those women with two
pregnancies, 7.5% would consider termination for blindness; and
for those women with three or more pregnancies, 30.0% would
consider termination for blindness (P value = .03). There was also
no difference in preferences for TOP for any of the conditions when
comparing respondents who had a previous pregnancy affected with
a congenital anomaly (n = 4) to those who either were unsure or had
not had a previous pregnancy affected with a congenital anomaly
(n = 77).
Conditions associated with a shortened lifespan were highly
predictive of a “yes” response to desire for PNT or consideration of
termination (P < .0001). The odds ratio was 2.60, meaning the odds
of answering “yes” when a condition was associated with a shortenedlifespan was 2.60 times the odds of answering “yes” when the condi-
tion was not associated with a shortened lifespan.4 | DISCUSSION
Here, we show there is broad interest for prenatal genetic services
among pregnant women at SPHMMC in Addis Ababa. Most
surveyed women were interested in PNT for all queried conditions
with women more likely to express interest in TOP for conditions
associated with a shortened lifespan. The data presented here for
the first time show the potential for prenatal genetic testing and
termination of affected pregnancies as a potential tool to address
the growing relative incidence of NCDs in low‐income countries.
This is especially true considering that congenital anomalies are the
most common NCD cause of death in individuals less than 5 years
of age, with congenital heart defects, neural tube defects, hemoglo-
binopathies, Down syndrome, and G6PD deficiency, the most com-
mon worldwide.4,33
To date, there has been limited research focused on prenatal
genetic testing in low‐income countries.18 Ross et al described patient
preferences for sickle cell disease prenatal testing in Ghana but did not
address TOP of affected pregnancies.18 Additional work in Cameroon
(a lower middle‐income country) also focused on sickle cell disease but
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ous work overall showed patient interest in both PNT and TOP for
sickle cell disease. Important to note, most recruited patients had
either a personal history of sickle cell disease or a family member with
the condition. Here, we assessed the Ethiopian public's preferences
for PNT and TOP with a limited number of surveyed individuals having
had a child with a congenital anomaly or suspected genetic condition.
Even with these differences, there exists similar preferences for PNT
between the Ghana and Cameroon studies and our own for conditions
surveyed, with similar technological and resource barriers precluding
their implementation.8,18,34
In our cohort, there was broad interest in PNT, which held true
based on a number of variables, including age, gestational age,
previous number of pregnancies, and having a previous child with a
known congenital anomaly. When considering TOP for the same
conditions, there was less interest, but women were more likely to
express TOP interest for conditions associated with a shortened
lifespan. This pattern of responses suggests women are interested in
identifying if their child is affected with a condition but may not
always be interested in termination, especially if the conditions are
not associated with a shortened lifespan. This widespread interest
for prenatal testing with less interest in TOP supports the importance
of expanding medical genetic services throughout Ethiopia. Patient
interest for the early diagnosis of these conditions is best supported
through the education and counseling of patients on the many aspects
of care for affected individuals. Increasing genetic counseling services
in Ethiopia, especially services targeting obstetrical and pediatric pop-
ulations, would help families understand and adapt to the medical,
psychological, and familial implications of the diagnosed condition.
As these services are limited in Ethiopia, it will be important to assess
if preferences for TOP are different before and after genetic counsel-
ing delivery.
For almost all conditions surveyed, there was little variability
between the responses in the four different subsamples—age,
gestational age, number of pregnancies, and having a previous child
with a congenital anomaly. The one exception was blindness in which
significantly fewer women above a gestational age of 34.5 weeks
would consider TOP. Furthermore, the highest TOP rate for blindness
occurred in women with three or more previous pregnancies (30.0%),
while the lowest rate is seen in women who had two pregnancies
(7.5%). The reasons for these responses have not been fully elucidated
at this time. Blindness poses a major public health problem in Ethiopia
and worldwide with it estimated in low‐income countries that 60% to
80% of blind children die within 1 to 2 years of becoming blind.35,36
Further study is needed to address why these differences were
present in our study.
The importance of this work is further evident when considered
with related studies in other countries.8,15-21 These studies suggest
most women desire some form of prenatal testing in both developed
and developing nations and most would consider termination for at
least some conditions. However, the attitudes towards individual med-
ical conditions differ among various societies and ethnic groups
suggesting there may be difficulties with recommending prenataltesting for a universal panel of conditions. Our data support this when
considering the increased interest in PNT and TOP for blindness and
amelia, both conditions not associated with a significant shortening
of lifespan in high‐income countries. However, Ahmed et al showed
that less than 40% of British Pakistani mothers were interested in
PNT for amelia compared with 93% of women in our data, illustrating
a variation in opinion between groups.15
Patients' decision to proceed with TOP is influenced by multiple
factors including medical provider recommendations and the personal
values and belief systems of the individual and their support
network.37 In our study, patients were more likely to express interest
in TOP for conditions associated with a shortened lifespan.
These congenital anomalies and genetic conditions typically entail a
large emotional burden and financial cost on the woman and her
family, which may be difficult to handle with the already high burden
of health care constraints in a developing nation.38 As an example,
in Ethiopia, patients affected with a neural tube defect were required
to wait 447 days for neurosurgical services and had to travel 300 miles
on average to receive these services.39 Similar difficulties may at least
partially explain patients' interest in PNT and TOP for other conditions
included in the survey.
While the data presented here will prove useful for future public
health planning, such as influencing policy decisions and prioritizing
resources for prenatal testing, there are a number of limitations.
Our survey was limited to one public institution and did not evaluate
ethnicity, religion, education, or socioeconomic background of partici-
pants. Furthermore, only a small subset of pregnant women were
surveyed. Additionally, the women surveyed had little time to consider
their responses and likely had limited knowledge surrounding the
conditions. The survey was also overseen by Western researchers,
which could have falsely inflated acceptance of prenatal services.
With small numbers of participants in some of the statistical
groups, there was limited power to make conclusions in some cases.
A potential limitation was that the type of PNT was not specified to
account for the full spectrum of PNT available, including ultrasound‐
diagnosable conditions and those that would require advanced PNT
such as certain forms of hearing loss, blindness, and epilepsy.
Resultantly, questions were not tailored to current options in
Ethiopia.
Future work should include fathers and other family members who
have important input when an individual considers PNT and TOP.40,41
Additionally, investigating the Ethiopian public's attitudes towards dis-
ability and their perception of TOP will be necessary to fully appreci-
ate the implications of PNT and TOP. We chose to assess if patients
were more interested in services for conditions associated with a
shortened lifespan. There are numerous other factors that contribute
to a patient's desire to undergo PNT and TOP that were not assessed
here. Future study combined with qualitative data would provide
information into these other important condition‐specific elements,
which may better inform clinical practice. While we used lifespan to
assess differences between patient interests in TOP, there are certain
to be patient‐specific differences in interest. Resultantly, the presence
or absence of a condition associated with a shortened lifespan should
BROOKS ET AL. 601not be used as a primary determinant of whether or not a patient is
offered PNT or TOP.5 | CONCLUSION
Our work provides preliminary evidence that prenatal diagnostic
services and the option for termination is a publicly accepted strategy
to address congenital anomalies and genetic diseases in Ethiopia.
While it is attractive to consider the potential benefits of PNT and
TOP for certain congenital anomalies and genetic conditions, consider-
ing their appropriateness for the patient population is paramount.
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